SAKK – YOUNG ONCOLOGY ACADEMY - Was junge Onkologen von ESMO - EHA - ESTRO und ESP berichten — European Society for Medical Oncology (ESMO) Congress 2024
Pembrolizumab dose reduction in metastatic NSCLC – an opportunity for improving cost-effectiveness?
There were many new developments, including practice-changing clinical trials, presented at this year’s European Society of Medical Oncology (ESMO) Congress in Barcelona. From the vast number of abstracts available in the rapidly evolving field of thoracic oncology, we have selected one abstract that was of particular interest to us: Low-dose versus standard dose pembrolizumab for treatment of advanced-stage non-small cell lung cancer (NSCLC) – Results of the pre-planned interim analysis of the clinical trial NVALT-30